The Cassava Sciences saga: Short sellers, ‘gaming’ the FDA, and the damaging ripple effects
By 
Jaclyn Jaeger2022-03-02T19:48:00
The Federal Drug Administration’s decision last month to deny a citizen petition on behalf of short sellers with positions in Cassava Sciences stock highlights the damage the commonly exploited regulatory process can have on a company, regardless of innocence or guilt.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleDOJ probe into shadowy underworld of short selling ‘long overdue’
A Department of Justice criminal investigation into illegal short selling is just the latest indication these schemes demand greater scrutiny that chief compliance officers and in-house counsel can no longer afford to ignore.
-
ArticleU.K. government scraps long-awaited audit reforms to prioritize growth
Long-awaited reforms to the U.K. audit regime have been “scrapped” from the government’s legislative plans. The decision has led to an outburst of disappointment and frustration from audit bodies and pension funds that argued the reforms would increase trust in companies and support growth.
-
ArticleSix AI questions compliance officers must answer in 2026
As artificial intelligence reshapes business, compliance teams face new questions about risk and oversight. These are the key issues compliance professionals should be asking as they evaluate their programs heading into 2026.
More from Risk Management
-
ArticleCompliance must prepare for post-quantum cryptography requirements in contracts
While companies focus on the risks, opportunities, and regulations emerging around AI, the next tech challenge is already on the horizon. Quantum computers are here – and so are the associated crime risks, plus some encryption protections.
-
ArticleRapid regulatory change requires investment in compliance processes in financial services firms
Geopolitical instability and a general focus on increasing growth and productivity by governments worldwide are causing a slew of regulatory changes in the financial services sector. But most firms are failing to identify potential compliance changes early enough to make meaningful decisions.
-
ArticleCompliance should protect firms from AI-washing investigations and insurance claims
Insurance firms are warning that AI-washing could trigger a slew of cases against directors, and are adjusting their directors’ and officers’ liability premiums accordingly. With regulators cracking down on AI-washing, compliance could be a crucial line of defense and save companies on their insurance costs.